• bit.bio has undertaken a COVID-19 risk assessment and we are COVID secure
  • info@bit.bio
  • +44 (0) 1223 787 297
Bit Bio
    • technology
    • about
      • who we are
      • team
      • spotlights
      • careers
      • sustainability
      • partner with us
    • ioCells
      • ioWild Type Cells
        • ioGlutamatergic Neurons
        • ioSkeletal Myocytes
        • ioGABAergic Neurons
      • ioDisease Model
        • ioGlutamatergic Neurons HTT 50CAG/WT
    • resources
      • bits of bio
      • blog
      • journals
      • posters
      • tutorial videos
      • videos
      • webinars
    • news
    • events
    • contact
    • technology
    • about
      • who we are
      • team
      • spotlights
      • careers
      • sustainability
      • partner with us
    • ioCells
      • ioWild Type Cells
        • ioGlutamatergic Neurons
        • ioSkeletal Myocytes
        • ioGABAergic Neurons
      • ioDisease Model
        • ioGlutamatergic Neurons HTT 50CAG/WT
    • resources
      • bits of bio
      • blog
      • journals
      • posters
      • tutorial videos
      • videos
      • webinars
    • news
    • events
    • contact

    News

    Article | This Startup Is Making — and Programming — Human Cells

    Article | This Startup Is Making — and Programming — Human Cells

    Dec 21, 2021

    Published by Wired

    read more
    Article | bit.bio CEO features in Charles River Laboratories Disruptor series

    Article | bit.bio CEO features in Charles River Laboratories Disruptor series

    Nov 30, 2021

    Published by CRL Disruptors

    read more
    Article | Takeda oncology vet joins bit.bio as COO

    Article | Takeda oncology vet joins bit.bio as COO

    Nov 19, 2021

    Published by Endpoints News

    read more
    Press release | bit.bio appoints Kathryn Corzo as Chief Operating Officer

    Press release | bit.bio appoints Kathryn Corzo as Chief Operating Officer

    Nov 17, 2021

    Published by bit.bio

    read more
    Press release | bit.bio signs up to race to zero as part of COP26

    Press release | bit.bio signs up to race to zero as part of COP26

    Nov 10, 2021

    Published by bit.bio

    read more
    Article | bit.bio adds $100M+ investments and board of directors

    Article | bit.bio adds $100M+ investments and board of directors

    Nov 5, 2021

    Published by Endpoints News

    read more
    Press release | bit.bio raises $103 million in first close of Series B financing

    Press release | bit.bio raises $103 million in first close of Series B financing

    Nov 5, 2021

    Published by bit.bio

    read more
    Press release | bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate

    Press release | bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate

    Oct 25, 2021

    Published by bit.bio

    read more
    Article | Q&A with our Head of Phenotyping | Bringing academia and business together

    Article | Q&A with our Head of Phenotyping | Bringing academia and business together

    Oct 21, 2021

    Published by Academy of Medical Sciences

    read more
    Page 3 of 9 « 1 2 3 4 5 »

    Navigation

    • technology
    • about
    • careers
    • partner with us
    • resources
    • news
    • events
    • contact

    Products

    • ioGlutamatergic Neurons
    • ioSkeletal Myocytes
    • ioGABAergic Neurons
    • ioGlutamatergic Neurons HTT

    Subscribe to our newsletter

    ×

    Subscribe to our newsletter

    bit.bio © 2022 | All rights reserved | privacy policy | terms & conditions

    bit.bio © 2021 | All rights reserved
    privacy policy | terms & conditions